UK healthcare cost agency rejects J&J's nasal spray for depression
Share:
(Reuters) - Britain's healthcare cost agency on Tuesday recommended against including Johnson & Johnson's nasal spray for depression, Spravato, in the country's healthcare network, citing uncertainties over its clinical and cost effectiveness.The National Institute for Health and Care Excellence (NICE), which determines if a drug is included in Britain's National Healthcare System (NHS), said there was a lack of evidence on how the treatment, chemically called esketamine, fared over rivals, and..